AT
BCRX icon

Arlington Trust’s BioCryst Pharmaceuticals BCRX Stock Holding History

Arlington Trust’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.33K Buy
400
+250
+167% +$2.35K ﹤0.01% 693
2026
Q2 		$1.5K Buy
+150
New +$1.36K ﹤0.01% 706

Other funds holding BCRX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Wedge Capital Management
Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return
Inspire Investing
Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return
Doliver Advisors
Doliver Advisors Houston, Texas $458M AUM 38.24% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
May Barnhard Investments
May Barnhard Investments Bethesda, Maryland $243M AUM 13.89% 1-Year Est. Return
Contravisory Investment Management
Contravisory Investment Management Norwell, Massachusetts $552M AUM 32.44% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Bender Robert & Associates
Bender Robert & Associates Pasadena, California $525M AUM 38.43% 1-Year Est. Return
Cypress Wealth Services
Cypress Wealth Services Palm Desert, California $848M AUM 19.63% 1-Year Est. Return

Arlington Trust's BCRX Position: Q3 2026 in Review

Arlington Trust increased its BioCryst Pharmaceuticals (BCRX) stake by 167% in Q3 2026, buying an estimated $2.35K and bringing the position to 400 shares worth $3.33K. The position accounts for ﹤0.01% of the portfolio, ranked #693.

Arlington Trust first reported a position in BCRX in Q2 2026 and has held it in 2 quarters since. 32 funds tracked by Wall St. Rank hold BCRX as of Q3 2026.

  • Arlington Trust held 400 shares of BioCryst Pharmaceuticals worth $3.33K as of Q3 2026.
  • Arlington Trust bought 250 BioCryst Pharmaceuticals shares in Q3 2026, an estimated $2.35K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Arlington Trust's portfolio in Q3 2026, its #693 holding.
  • Arlington Trust first reported a position in BioCryst Pharmaceuticals in Q2 2026 and has held it in 2 quarters since.
  • 32 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2026.

Based on Arlington Trust's 13F filing for Q3 2026, filed 20 Oct 2026.